Literature DB >> 1654396

The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus.

M Dieterich1, A Straube, T Brandt, W Paulus, U Büttner.   

Abstract

The GABAergic drug baclofen and the cholinergic drug physostigmine were administered to patients with upbeat and downbeat nystagmus. Baclofen (orally, 5 mg three times daily) reduced nystagmus slow phase velocity and distressing oscillopsia by 25-75% in four out of five patients (two upbeat nystagmus; two downbeat nystagmus). Physostigmine (1 mg single intravenous injection) increased nystagmus in five additional patients with downbeat (1) or positional downbeat nystagmus (4) for a duration of 15-20 minutes. The different interactions of baclofen and physostigmine on neurotransmission subserving vertical vestibulo-ocular reflex could account for these effects. The response to baclofen appears to be a GABA-B-ergic effect with augmentation of the physiological inhibitory influence of the vestibulo-cerebellum on the vestibular nuclei. Similarly baclofen has an inhibitory effect on the velocity storage mechanism. Cholinergic action may cause the increment of nystagmus by physostigmine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654396      PMCID: PMC1014435          DOI: 10.1136/jnnp.54.7.627

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  36 in total

1.  Analysis of downbeat nystagmus. Otolithic vs semicircular canal influences.

Authors:  M Gresty; H Barratt; P Rudge; N Page
Journal:  Arch Neurol       Date:  1986-01

2.  Aperiodic alternating nystagmus: report of two cases and treatment by baclofen.

Authors:  D Nuti; G Ciacci; F Giannini; A Rossi; A Federico
Journal:  Ital J Neurol Sci       Date:  1986-08

3.  Upbeat nystagmus and the ventral tegmental pathway of the upward vestibulo-ocular reflex.

Authors:  P J Ranalli; J A Sharpe
Journal:  Neurology       Date:  1988-08       Impact factor: 9.910

4.  The influence of physostigmine on visual-vestibular interaction in hereditary ataxias.

Authors:  C C Tijssen; L J Endtz; C Goor
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-10       Impact factor: 10.154

5.  Baclofen and velocity storage: a model of the effects of the drug on the vestibulo-ocular reflex in the rhesus monkey.

Authors:  B Cohen; D Helwig; T Raphan
Journal:  J Physiol       Date:  1987-12       Impact factor: 5.182

6.  Effectiveness of trihexyphenidyl against pendular nystagmus and palatal myoclonus: evidence of cholinergic dysfunction.

Authors:  B Jabbari; M Rosenberg; B Scherokman; C H Gunderson; J W McBurney; W McClintock
Journal:  Mov Disord       Date:  1987       Impact factor: 10.338

7.  Medical treatment of nystagmus and ocular motor disorders.

Authors:  T J Carlow
Journal:  Int Ophthalmol Clin       Date:  1986

8.  Lateropulsion and upbeat nystagmus are manifestations of central vestibular dysfunction.

Authors:  E E Benjamin; C F Zimmerman; B T Troost
Journal:  Arch Neurol       Date:  1986-09

9.  Tobacco-induced primary-position upbeat nystagmus.

Authors:  P A Sibony; C Evinger; K A Manning
Journal:  Ann Neurol       Date:  1987-01       Impact factor: 10.422

10.  Upbeat nystagmus: clinicopathologic study of two patients.

Authors:  J R Keane; H H Itabashi
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

View more
  18 in total

1.  Treatment of nystagmus.

Authors:  Matthew J Thurtell; R John Leigh
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

2.  Acquired Nystagmus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

3.  Upbeat nystagmus as a clinical sign of physostigmine-induced right occipital non-convulsive status epilepticus.

Authors:  H Neugebauer; T Winkler; B Feddersen; H W Pfister; S Noachtar; A Straube; T Pfefferkorn
Journal:  J Neurol       Date:  2011-10-01       Impact factor: 4.849

4.  Crossover trial of gabapentin and memantine as treatment for acquired nystagmus.

Authors:  Matthew J Thurtell; Anand C Joshi; Alice C Leone; Robert L Tomsak; Gregory S Kosmorsky; John S Stahl; R John Leigh
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

5.  Current treatment of vestibular, ocular motor disorders and nystagmus.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

6.  Roving Eye Movements.

Authors:  Marie N Dibra; Richard B Berry; Mary H Wagner; Scott M Ryals
Journal:  J Clin Sleep Med       Date:  2018-10-15       Impact factor: 4.062

7.  Transition from downbeat to upbeat nystagmus caused by 4-aminopyridine.

Authors:  K Feil; J Claaßen; S Bardins; J Teufel; M Habs; R Kalla; M Strupp
Journal:  J Neurol       Date:  2013-04-18       Impact factor: 4.849

8.  Natural course of positional down-beating nystagmus of peripheral origin.

Authors:  Jacopo Cambi; Serena Astore; Marco Mandalà; Franco Trabalzini; Daniele Nuti
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

9.  [Pharmacological treatment of nystagmus].

Authors:  C Pieh-Beisse; W A Lagrèze
Journal:  Ophthalmologe       Date:  2011-02       Impact factor: 1.059

10.  Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin.

Authors:  Michaela Starck; Holger Albrecht; Walter Pöllmann; Marianne Dieterich; Andreas Straube
Journal:  J Neurol       Date:  2009-09-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.